Last updated on July 2019

A Study of the Safety Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease


Brief description of study

This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.

Detailed Study Description

A multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) > 22, who are to start up-titration with methotrexate.

The study will be conducted in two parts separated by an interim analysis.

Part 1: The subjects will be randomized in a 1:1:1 ratio into: .

  • AP1189 dose 50 mg
  • AP1189 dose 100 mg
  • placebo

INTERIM ANALYSIS

Part 2: All subjects will be randomized into either design 1, 2 or 3 based on data from the interim analysis.

  • Design 1: AP1189 dose 50 mg or placebo in a 2:1 ratio
  • Design 2: AP1189 dose 100 mg or placebo in a 2:1 ratio
  • Design 3: Continue with the same doses as in Part 1

The purpose of this study is to determine the safety and efficacy of 2 doses of AP1189 compared with placebo after 4 weeks of treatment.

Clinical Study Identifier: NCT04004429

Find a site near you

Start Over